CD3 Use Survey |
Welcome
Dear CD3 G.L.O.V.E User,
We have been contacted by Complaint Technologies to survey users of the CD3 G.L.O.V.E. and other CD3 technology to learn about their uses and perceived effectiveness. Your survey answers are very important for helping to gain insights about using CD3 technology.
Please be frank and honest. Your answers will be kept strictly confidential, and only the researchers will receive the completed surveys. Your answers will be combined with others’ answers, so that no one can identify individual responses. No individual results will be published or made available to any person or organization. The only information released will be the findings, and then only in aggregate form, void of any specific agency.
By completing the survey, you are consenting to the use of this information for research purposes. Your professional opinion could help shape and improve the training program on CD3 technologies.
Thanks for your kind assistance. Completion of the questionnaire is important, so please take the time to complete the entire survey. Read the questions and answers carefully before answering them.
Professionally yours,
John G. Peters, Jr., Ph.D.
Darrell L. Ross, Ph.D.
We have been contacted by Complaint Technologies to survey users of the CD3 G.L.O.V.E. and other CD3 technology to learn about their uses and perceived effectiveness. Your survey answers are very important for helping to gain insights about using CD3 technology.
Please be frank and honest. Your answers will be kept strictly confidential, and only the researchers will receive the completed surveys. Your answers will be combined with others’ answers, so that no one can identify individual responses. No individual results will be published or made available to any person or organization. The only information released will be the findings, and then only in aggregate form, void of any specific agency.
By completing the survey, you are consenting to the use of this information for research purposes. Your professional opinion could help shape and improve the training program on CD3 technologies.
Thanks for your kind assistance. Completion of the questionnaire is important, so please take the time to complete the entire survey. Read the questions and answers carefully before answering them.
Professionally yours,
John G. Peters, Jr., Ph.D.
Darrell L. Ross, Ph.D.